References
- 1. G. Ganzetti, A. Campanati and A. Offidani, Non-alcoholic fatty liver disease and psoriasis: So far, so near, World J. Hepatol. 7 (2015) 315-326; DOI: 10.4254/wjh.v7.i3.315.10.4254/wjh.v7.i3.315438116025848461
- 2. A. Kotronen and H. Yki-Jarvinen, Fatty liver: a novel component of the metabolic syndrome, Arterioscler. Thromb. Vasc. Biol. 28 (2008) 27-38; DOI: ATVBAHA.107.147538.10.1161/ATVBAHA.107.14753817690317
- 3. M. Takeuchi, J. Takino, A. Sakasai-Sakai, T. Takata, T. Ueda, M. Tsutsumi, H. Hyogo and S. Yamagishi, Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies, World J. Hepatol. 6 (2014) 880-893; DOI: 10.4254/wjh.v6.i12.880.10.4254/wjh.v6.i12.880426990725544875
- 4. C. S. Hsu and J. H. Kao, Non-alcoholic fatty liver disease: an emerging liver disease in Taiwan, J. Formos. Med. Assoc. 111 (2012) 527-535; DOI: 10.1016/j.jfma.2012.07.002.10.1016/j.jfma.2012.07.00223089687
- 5. A. S. Bodzin and R. W. Busuttil, Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome, World J. Hepatol. 7 (2015) 1157-1167; DOI: 10.4254/wjh.v7.i9.1157.10.4254/wjh.v7.i9.1157443849126019732
- 6. P. Loria, A. Lonardo, L. Carulli, A. M. Verrone, M. Ricchi, S. Lombardini, A. Rudilosso, S. Ballestri and N. Carulli, Review article: the metabolic syndrome and non-alcoholic fatty liver disease, Aliment. Pharmacol. Ther. 22 (Suppl 2) (2005) 31-36; DOI: APT2592.
- 7. D. Papandreou and E. Andreou, Role of diet on non-alcoholic fatty liver disease: An updated narrative review, World J. Hepatol. 7 (2015) 575-582; DOI: 10.4254/wjh.v7.i3.575.10.4254/wjh.v7.i3.575438118025848481
- 8. C. P. Day and O. F. James, Steatohepatitis: a tale of two “hits”?, Gastroenterology 114 (1998) 842-845; DOI: S0016508598003564.
- 9. P. Angulo, Nonalcoholic fatty liver disease, N. Engl. J. Med. 346 (2002) 1221-1231; DOI: 10.1056/ NEJMra011775.10.1056/NEJMra01177511961152
- 10. A. Takaki, D. Kawai and K. Yamamoto, Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH), Int. J. Mol. Sci. 14 (2013) 20704-20728; DOI: 10.3390/ijms141020704.10.3390/ijms141020704382163924132155
- 11. H. Tilg and A. R. Moschen, Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis, Hepatology 52 (2010) 1836-1846; DOI: 10.1002/hep.24001.10.1002/hep.2400121038418
- 12. W. Tomeno, M. Yoneda, K. Imajo, Y. Ogawa, T. Kessoku, S. Saito, Y. Eguchi and A. Nakajima, Emerging drugs for non-alcoholic steatohepatitis, Expert Opin. Emerg. Drugs 18 (2013) 279-290; DOI: 10.1517/14728214.2013.811232.10.1517/14728214.2013.81123223848366
- 13. Y. Takahashi, K. Sugimoto, H. Inui and T. Fukusato, Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, World J. Gastroenterol. 21 (2015) 3777-3785; DOI: 10.3748/wjg.v21.i13.3777.10.3748/wjg.v21.i13.3777438552525852263
- 14. S. R. Pyper, N. Viswakarma, S. Yu and J. K. Reddy, PPARalpha: energy combustion, hypolipidemia, inflammation and cancer, Nucl. Recept. Signal. 8 (2010) e002; DOI: 10.1621/nrs.08002.10.1621/nrs.08002285826620414453
- 15. K. S. Kilgore and A. N. Billin, PPARbeta/delta ligands as modulators of the inflammatory response, Curr. Opin. Invest. Drugs 9 (2008) 463-469.
- 16. S. J. Bensinger and P. Tontonoz, Integration of metabolism and inflammation by lipid-activated nuclear receptors, Nature 454 (2008) 470-477; DOI: 10.1038/nature07202.10.1038/nature0720218650918
- 17. L. Zeng, W. J. Tang, J. J. Yin and B. J. Zhou, Signal transductions and nonalcoholic fatty liver: a mini-review, Int. J. Clin. Exp. Med. 7 (2014) 1624-1631.
- 18. L. Michalik, J. Auwerx, J. P. Berger, V. K. Chatterjee, C. K. Glass, F. J. Gonzalez, P. A. Grimaldi, T. Kadowaki, M. A. Lazar, S. O’Rahilly, C. N. A. Palmer, J. Plutzky, J. K. Reddy, B. M. Spiegelman, B.Staels and W. Wahli, International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors, Pharmacol. Rev. 58 (2006) 726-741; DOI: 10.1124/pr.58.4.5 58/4/726 [pii ].10.1124/pr.58.4.517132851
- 19. D. Usuda and T. Kanda, Peroxisome proliferator-activated receptors for hypertension, World J. Cardiol. 6 (2014) 744-754; DOI: 10.4330/wjc.v6.i8.744.10.4330/wjc.v6.i8.744416370325228953
- 20. V. T. Samuel and G. I. Shulman, Mechanisms for insulin resistance: common threads and missing links, Cell 148 (2012) 852-871; DOI: 10.1016/j.cell.2012.02.017.10.1016/j.cell.2012.02.017329442022385956
- 21. F. Kim, M. Pham, E. Maloney, N. O. Rizzo, G. J. Morton, B. E. Wisse, E. A. Kirk, A. Chait and M. W. Schwartz, Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance, Arterioscler. Thromb. Vasc. Biol. 28 (2008) 1982-1988; DOI: 10.1161/ATVBAHA.108.169722.10.1161/ATVBAHA.108.169722257757518772497
- 22. S. H. Caldwell, E. E. Hespenheide, J. A. Redick, J. C. Iezzoni, E. H. Battle and B. L. Sheppard, A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis, Am. J. Gastroenterol. 96 (2001) 519-525; DOI: S0002-9270(00)02346-7.10.1111/j.1572-0241.2001.03553.x11232700
- 23. E. Frohlich and R. Wahl, Chemotherapy and chemoprevention by thiazolidinediones, Biomed. Res. Int. 2015 (2015) Article ID 845340; DOI: 10.1155/2015/845340.10.1155/2015/845340438343825866814
- 24. H. B. Bhatt and R. J. Smith, Fatty liver disease in diabetes mellitus, Hepatobil. Surg. Nutr. 4 (2015) 101-108; DOI: 10.3978/j.issn.2304-3881.2015.01.03.
- 25. M. O. Rakoski, A. G. Singal, M. A. Rogers and H. Conjeevaram, Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis, Aliment. Pharmacol. Ther. 32 (2010) 1211-1221; DOI: 10.1111/j.1365-2036.2010.04467.x.10.1111/j.1365-2036.2010.04467.x20955440
- 26. A. S. Laganá, S. G. Vitale, A. Nigro, V. Sofo, F. M. Salmeri, P. Rossetti, A. M. C. Rapisarda, S. La Vignera, R. A. Condorelli, G. Rizzo and M. Buscema, Pleiotropic Actions of peroxisome proliferator-activated receptors (PPARs) in dysregulated metabolic homeostasis, inflammation and cancer: Current evidence and future perspectives, Int. J. Mol. Sci. 17 (2016) Article ID 999 (10 pp); DOI: 10.3390/ijms17070999.10.3390/ijms17070999496437527347932
- 27. C. Ning, L. Liu, G. Lv, Y. Yang, Y. Zhang, R. Yu, Y. Wang and J. Zhu, Lipid metabolism and inflammation modulated by vitamin D in liver of diabetic rats, Lipids Health Dis. 14 (2015) Article ID 31 (9 pages); DOI: 10.1186/s12944-015-0030-5.10.1186/s12944-015-0030-5440621925899686
- 28. G. Sabio, M. Das, A. Mora, Z. Zhang, J. Y. Jun, H. J. Ko, T. Barrett, J. K. Kim and R. J. Davis, A stress signaling pathway in adipose tissue regulates hepatic insulin resistance, Science 322 (2008) 1539- 1543; DOI: 10.1126/science.1160794.10.1126/science.1160794264302619056984
- 29. J. H. Peng, T. Cui, Z. L. Sun, F. Huang, L. Chen, L. Xu, Q. Feng and Y. Y. Hu, Effects of Puerariae radix extract on endotoxin receptors and TNF-alpha expression induced by gut-derived endotoxin in chronic alcoholic liver injury, Evid. Based Complement. Alternat. Med. 2012 (2012) Article ID 234987; DOI: 10.1155/2012/234987.10.1155/2012/234987348552023133491
- 30. Y. Ma, M. Gao, H. Sun and D. Liu, Interleukin-6 gene transfer reverses body weight gain and fatty liver in obese mice, Biochim. Biophys. Acta 1852 (2015) 1001-1011; DOI: 10.1016/j.bbadis.2015.01.017.10.1016/j.bbadis.2015.01.01725660446
- 31. G. Paredes-Turrubiarte, A. González-Chavez, R. Pérez-Tamayo, B. Y. Salazar-Vázquez, V. S. Hernández, N. Garibay-Nieto, J. M. Fragoso and G. Escobedo, Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients, Clin. Exp. Med. 16 (2016) 193-201; DOI: 10.1007/s10238-015-0347-4.10.1007/s10238-015-0347-425894568
- 32. X. Lin, Z. Zhang, J. M. Chen, Y. Y. Xu, H. R. Ye, J. Cui, Y. Fang, Y. Jin, D. R. Zhu and L. Yuan, Role of APN and TNF-alpha in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease, Genet. Mol. Res. 14 (2015) 2940-2946; DOI: 10.4238/2015.April.10.1.10.4238/2015.April.10.125966055
- 33. Q. Lv, Q. Zhen, L. Liu, R. Gao, S. Yang, H. Zhou, R. Goswami and Q. Li, AMP-kinase pathway is involved in tumor necrosis factor alpha-induced lipid accumulation in human hepatoma cells, Life Sci. 131 (2015) 23-29; DOI: 10.1016/j.lfs.2015.03.003.10.1016/j.lfs.2015.03.00325817233
- 34. C. Wang, G. Zhou and Z. Zeng, Effects of peroxisome proliferator-activated receptor-beta/delta on sepsis induced acute lung injury, Chin. Med. J. 127 (2014) 2129-2137.
- 35. L. M. Jiménez-Flores, S. López-Briones, M. H. Macías-Cervantes, J. Ramírez-Emiliano and V. Pérez-Vázquez, A PPARy, NF-kB and AMPK-dependent mechanism may be involved in the beneficial effects of curcumin in the diabetic db/db mice liver, Molecules 19 (2014) 8289-8302; DOI: 10.3390/molecules19068289.10.3390/molecules19068289627162024945581
- 36. Y. Shiomi, T. Yamauchi, M. Iwabu, M. Okada-Iwabu, R. Nakayama, Y. Orikawa, Y. Yoshioka, K. Tanaka, K. Ueki and T. Kadowaki, A novel peroxisome proliferator-activated receptor (PPAR)alpha agonist and PPARgamma antagonist, Z-551, ameliorates high-fat diet-induced obesity and metabolic disorders in mice, J. Biol. Chem. 290 (2015) Article ID 14567-81; DOI: jbc.M114.622191.
- 37. K. L. Lannan, J. Sahler, N. Kim, S. L. Spinelli, S. B. Maggirwar, O. Garraud, F. Cognasse, N. Blumberg and R. P. Phipps, Breaking the mold: transcription factors in the anucleate platelet and platelet- derived microparticles, Front. Immunol. 6 (2015) Article ID 48; DOI: 10.3389/fimmu.2015.00048.10.3389/fimmu.2015.00048432762125762994
- 38. M. Capanni, F. Calella, M. R. Biagini, S. Genise, L. Raimondi, G. Bedogni, G. Svegliati-Baroni, F. Sofi, S. Milani, R. Abbate, C. Surrenti and A. Casini, Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study, Aliment. Pharmacol. Ther. 23 (2006) 1143-1151; DOI: 10.1111/j.1365-2036.2006.02885.x.10.1111/j.1365-2036.2006.02885.x16611275
- 39. L. Li, L. Chen, X. Lin, Y. Xu, J. Ren, J. Fu and Y. Qiu, Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats, J. Pharmacol. Sci. 127 (2015) 244-250; DOI: 10.1016/j.jphs.2014.12.001.10.1016/j.jphs.2014.12.00125837920
- 40. N. Zhang, Y. Lu, X. Shen, Y. Bao, J. Cheng, L. Chen, B. Li and Q. Zhang, Fenofibrate treatment attenuated chronic endoplasmic reticulum stress in the liver of nonalcoholic fatty liver disease mice, Pharmacology 95 (2015) 173-180; DOI: 10.1159/000380952.10.1159/00038095225896720
- 41. P. Patel and H. Barkate, Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population, Indian J. Endocrinol. Metab. 20 (2016) 67-71; DOI: 10.4103/2230-8210.172243.10.4103/2230-8210.172243474338726904471
- 42. S. M. El-Haggar and T. M. Mostafa, Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease, Hepatol. Int. 9 (2015) 471-479; DOI: 10.1007/s12072-015-9633-1.10.1007/s12072-015-9633-125956613
- 43. T. Kopf, H. L. Schaefer, M. Troetzmueller, H. Koefeler, M. Broenstrup, T. Konovalova and G. Schmitz, Influence of fenofibrate treatment on triacylglycerides, diacylglycerides and fatty acids in fructose fed rats, PLOS ONE 9 (2014) e106849; DOI: 10.1371/journal.pone.0106849.10.1371/journal.pone.0106849415781125198467
- 44. R. L. Attridge, C. R. Frei, L. Ryan, J. Koeller and W. D. Linn, Fenofibrate-associated nephrotoxicity: a review of current evidence, Am. J. Health Syst. Pharm. 70 (2013) 1219-1225; DOI: 10.2146/ajhp120131.10.2146/ajhp12013123820458
- 45. X. M. Xin, M. X. Zhong, G. L. Yang, Y. Peng, Y. L. Zhang and W. Zhu, GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells, World J. Gastroenterol. 20 (2014) 15727-15735; DOI: 10.3748/wjg.v20.i42.15727.10.3748/wjg.v20.i42.15727422953725400456
- 46. K. Chehaibi, L. Cedo, J. Metso, X. Palomer, D. Santos, H. Quesada, M. Naceur Slimane, W. Wahli. J. Julve, M. Vazquez-Carrera, M. Jauhiainen, F. Blanco-Vaca and J. C. Escola-Gil, PPAR-beta/delta activation promotes phospholipid transfer protein expression, Biochem. Pharmacol. 94 (2015) 101-108; DOI: 10.1016/j.bcp.2015.01.016.10.1016/j.bcp.2015.01.01625662586
- 47. L. Salvado, E. Barroso, A. M. Gomez-Foix, X. Palomer, L. Michalik, W. Wahli and M. Vazquez- Carrera, PPARbeta/delta prevents endoplasmic reticulum stress-associated inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism, Diabetologia 57 (2014) 2126-2135; DOI: 10.1007/s00125-014-3331-8.10.1007/s00125-014-3331-825063273
- 48. Y. M. Attia, E. F. Elalkamy, O. A. Hammam, S. S. Mahmoud and A. S. El-Khatib, Telmisartan, an AT1 receptor blocker and a PPAR gamma activator, alleviates liver fibrosis induced experimentally by Schistosoma mansoni infection, Parasit. Vectors 6 (2013) Article ID 199; DOI: 10.1186/1756-3305-6-199.10.1186/1756-3305-6-199373392823829789
- 49. T. Izumi, F. Tsuruta, T. Ishizuka, K. Nakamura, M. Kothuma and M. Takahashi, Stereoselectivity in pharmacokinetics of rivoglitazone, a novel peroxisome proliferator-activated receptor gamma agonist, in rats and monkeys: model-based pharmacokinetic analysis and in vitro-in vivo extrapolation approach, J. Pharm. Sci. 102 (2013) 3174-3188; DOI: 10.1002/jps.23586.10.1002/jps.2358623686684
- 50. R. L. Koffarnus, K. A. Wargo and H. M. Phillippe, Rivoglitazone: a new thiazolidinedione for the treatment of type 2 diabetes mellitus, Ann. Pharmacother. 47 (2013) 877-885; DOI: 10.1345/aph.1R754.10.1345/aph.1R75423632280
- 51. B. Staels, A. Rubenstrunk, B. Noel, G. Rigou, P. Delataille, L. J. Millatt, M. Baron, A. Lucas, A. Tailleux, D. W. Hum, V. Ratziu, B. Cariou and R. Hanf, Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, Hepatology 58 (2013) 1941-1952; DOI: 10.1002/hep.26461.10.1002/hep.2646123703580
- 52. R. Hanf, L. J. Millatt, B. Cariou, B. Noel, G. Rigou, P. Delataille, V. Daix, D. W. Hum and B. Staels, The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects, Diab. Vasc. Dis. Res. 11 (2014) 440-447; DOI: 10.1177/1479164114548027.10.1177/147916411454802725212694
- 53. X. Zhao, J. Xue, X. L. Wang, Y. Zhang, M. Deng and M. L. Xie, Involvement of hepatic peroxisome proliferator-activated receptor alpha/gamma in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats, Int. Immunopharmacol. 22 (2014) 176-181; DOI: 10.1016/j. intimp.2014.06.032.
- 54. M. Bhaswant, H. Poudyal and L. Brown, Mechanisms of enhanced insulin secretion and sensitivity with n-3 unsaturated fatty acids, J. Nutr. Biochem. 26 (2015) 571-584; DOI: S0955-2863(15)00030-3.10.1016/j.jnutbio.2015.02.00125841249
- 55. T. D. Filippatos and M. S. Elisaf, Safety considerations with fenofibrate/simvastatin combination, Expert Opin. Drug Safety 14 (2015) 1481-1493; DOI: 10.1517/14740338.2015.1056778.10.1517/14740338.2015.105677826134595
- 56. G. Derosa and P. Maffioli, Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists on glycemic control, lipid profile and cardiovascular risk, Curr. Mol. Pharmacol. 5 (2012) 272-281; DOI: EPub-Abstract-CMP-51.10.2174/187446721120502027222122457
- 57. K. Wallenius, A. Kjellstedt, P. Thalén, L. Löfgren and N. D. Oakes, The PPARα/γ agonist, tesaglitazar, improves insulin mediated switching of tissue glucose and free fatty acid utilization in vivo in the obese zucker rat, PPAR Res. 2013 (2013) Article ID 305347 (14 pages); DOI: 10.1155/2013/305347.10.1155/2013/305347382632624285952
- 58. F. Gilardi, M. Giudici, N. Mitro, O. Maschi, U. Guerrini, G. Rando, A. Maggi, G. Cermenati, A. Laghezza, F. Loiodice, G. Pochetti, A. Lavecchia, D. Caruso, E. De Fabiani, K. Bamberg and M. Crestani, LT175 is a novel PPARalpha/gamma ligand with potent insulin-sensitizing effects and reduced adipogenic properties, J. Biol. Chem. 289 (2014) 6908-6920; DOI: 10.1074/jbc.M113.506394.10.1074/jbc.M113.506394394535224451380
- 59. L. S. Mackenzie and L. Lione, Harnessing the benefits of PPARbeta/delta agonists, Life Sci. 93 (2013) 963-967; DOI: 10.1016/j.lfs.2013.10.022. 10.1016/j.lfs.2013.10.02224184294
- 60. H. J. Gim, H. Li, J. H. Jeong, S. J. Lee, M. K. Sung, M. Y. Song, B. H. Park, S. J. Oh, J. H. Ryu and R. Jeon, Design, synthesis, and biological evaluation of a series of alkoxy-3-indolylacetic acids as peroxisome proliferator-activated receptor γ/δ agonists, Bioorg. Med. Chem. 23 (2015) 3322-3336; DOI: 10.1016/j.bmc.2015.04.046.10.1016/j.bmc.2015.04.04625982078
- 61. G. Gupta, G. Krishna, D. K. Chellappan, K. S. Gubbiyappa, M. Candasamy and K. Dua, Protective effect of pioglitazone, a PPARgamma agonist against acetaminophen-induced hepatotoxicity in rats, Mol. Cell. Biochem. 393 (2014) 223-228; DOI: 10.1007/s11010-014-2064-9.10.1007/s11010-014-2064-924771068
- 62. A. M. Lincoff, J. C. Tardif, G. G. Schwartz, S. J. Nicholls, L. Ryden, B. Neal, K. Malmberg, H. Wedel, J. B. Buse, R. R. Henry, A. Weichert, R. Cannata, A. Svensson, D. Volz and D. E. Grobbee, Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial, JAMA 311 (2014) 1515-1525; DOI: 10.1001/jama.2014.3321.10.1001/jama.2014.332124682069
- 63. X. C. Bao, Y. Q. Fang, P. You, S. Zhang and J. Ma, Protective role of peroxisome proliferator-activated receptor-beta/delta against pulmonary oxygen toxicity mediated through changes in NOS expression levels, Exp. Lung Res. 40 (2014) 105-116; DOI: 10.3109/01902148.2013.879497.10.3109/01902148.2013.87949724624894